Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Role of LRRK2 in the regulation of dopamine receptor trafficking.

Rassu M, Del Giudice MG, Sanna S, Taymans JM, Morari M, Brugnoli A, Frassineti M, Masala A, Esposito S, Galioto M, Valle C, Carri MT, Biosa A, Greggio E, Crosio C, Iaccarino C.

PLoS One. 2017 Jun 5;12(6):e0179082. doi: 10.1371/journal.pone.0179082. eCollection 2017.

2.

Neuroimaging in pre-motor Parkinson's disease.

Barber TR, Klein JC, Mackay CE, Hu MTM.

Neuroimage Clin. 2017 Apr 21;15:215-227. doi: 10.1016/j.nicl.2017.04.011. eCollection 2017. Review.

3.

LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease.

Bouhouche A, Tibar H, Ben El Haj R, El Bayad K, Razine R, Tazrout S, Skalli A, Bouslam N, Elouardi L, Benomar A, Yahyaoui M, Regragui W.

Parkinsons Dis. 2017;2017:2412486. doi: 10.1155/2017/2412486. Epub 2017 Mar 30.

4.

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.

Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M.

Acta Neuropathol Commun. 2017 Mar 14;5(1):22. doi: 10.1186/s40478-017-0426-8.

5.

Endogenous Leucine-Rich Repeat Kinase 2 Slows Synaptic Vesicle Recycling in Striatal Neurons.

Maas JW, Yang J, Edwards RH.

Front Synaptic Neurosci. 2017 Feb 23;9:5. doi: 10.3389/fnsyn.2017.00005. eCollection 2017.

6.

Mechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia.

Kim T, Vemuganti R.

J Cereb Blood Flow Metab. 2017 Jun;37(6):1910-1926. doi: 10.1177/0271678X17694186. Epub 2017 Jan 1.

7.

VPS35, the Retromer Complex and Parkinson's Disease.

Williams ET, Chen X, Moore DJ.

J Parkinsons Dis. 2017;7(2):219-233. doi: 10.3233/JPD-161020.

8.

Whole-exome sequencing of 228 patients with sporadic Parkinson's disease.

Sandor C, Honti F, Haerty W, Szewczyk-Krolikowski K, Tomlinson P, Evetts S, Millin S, Keane T, McCarthy SA, Durbin R, Talbot K, Hu M, Webber C, Ponting CP, Wade-Martins R.

Sci Rep. 2017 Jan 24;7:41188. doi: 10.1038/srep41188.

9.

PREDICT-PD: An online approach to prospectively identify risk indicators of Parkinson's disease.

Noyce AJ, R'Bibo L, Peress L, Bestwick JP, Adams-Carr KL, Mencacci NE, Hawkes CH, Masters JM, Wood N, Hardy J, Giovannoni G, Lees AJ, Schrag A.

Mov Disord. 2017 Feb;32(2):219-226. doi: 10.1002/mds.26898. Epub 2017 Jan 16.

10.

Parkinson's Disease and Cognitive Impairment.

Yang Y, Tang BS, Guo JF.

Parkinsons Dis. 2016;2016:6734678. doi: 10.1155/2016/6734678. Epub 2016 Dec 12. Review.

11.

LRRK2 inhibitors and their potential in the treatment of Parkinson's disease: current perspectives.

Atashrazm F, Dzamko N.

Clin Pharmacol. 2016 Oct 20;8:177-189. eCollection 2016. Review.

12.

Additional rare variant analysis in Parkinson's disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance.

Lubbe SJ, Escott-Price V, Gibbs JR, Nalls MA, Bras J, Price TR, Nicolas A, Jansen IE, Mok KY, Pittman AM, Tomkins JE, Lewis PA, Noyce AJ, Lesage S, Sharma M, Schiff ER, Levine AP, Brice A, Gasser T, Hardy J, Heutink P, Wood NW, Singleton AB, Williams NM, Morris HR; for International Parkinson’s Disease Genomics Consortium.

Hum Mol Genet. 2016 Dec 15;25(24):5483-5489. doi: 10.1093/hmg/ddw348.

13.

Polymer brain-nanotherapeutics for multipronged inhibition of microglial α-synuclein aggregation, activation, and neurotoxicity.

Bennett NK, Chmielowski R, Abdelhamid DS, Faig JJ, Francis N, Baum J, Pang ZP, Uhrich KE, Moghe PV.

Biomaterials. 2016 Dec;111:179-189. doi: 10.1016/j.biomaterials.2016.10.001. Epub 2016 Oct 4.

PMID:
27736702
14.

Drosophila Mutant Model of Parkinson's Disease Revealed an Unexpected Olfactory Performance: Morphofunctional Evidences.

De Rose F, Corda V, Solari P, Sacchetti P, Belcari A, Poddighe S, Kasture S, Solla P, Marrosu F, Liscia A.

Parkinsons Dis. 2016;2016:3508073. doi: 10.1155/2016/3508073. Epub 2016 Aug 28.

15.

Dopaminergic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects.

Borgs L, Peyre E, Alix P, Hanon K, Grobarczyk B, Godin JD, Purnelle A, Krusy N, Maquet P, Lefebvre P, Seutin V, Malgrange B, Nguyen L.

Sci Rep. 2016 Sep 19;6:33377. doi: 10.1038/srep33377.

16.

Disease-Toxicant Interactions in Parkinson's Disease Neuropathology.

Kwakye GF, McMinimy RA, Aschner M.

Neurochem Res. 2017 Jun;42(6):1772-1786. doi: 10.1007/s11064-016-2052-4. Epub 2016 Sep 9.

PMID:
27613618
17.

Genetic causes of Parkinson's disease in the Maltese: a study of selected mutations in LRRK2, MTHFR, QDPR and SPR.

Zahra C, Tabone C, Camilleri G, Felice AE, Farrugia R, Bezzina Wettinger S.

BMC Med Genet. 2016 Sep 9;17(1):65. doi: 10.1186/s12881-016-0327-x.

18.

Aging Shapes the Population-Mean and -Dispersion of Gene Expression in Human Brains.

Brinkmeyer-Langford CL, Guan J, Ji G, Cai JJ.

Front Aging Neurosci. 2016 Aug 3;8:183. doi: 10.3389/fnagi.2016.00183. eCollection 2016.

19.
20.

Arm swing as a potential new prodromal marker of Parkinson's disease.

Mirelman A, Bernad-Elazari H, Thaler A, Giladi-Yacobi E, Gurevich T, Gana-Weisz M, Saunders-Pullman R, Raymond D, Doan N, Bressman SB, Marder KS, Alcalay RN, Rao AK, Berg D, Brockmann K, Aasly J, Waro BJ, Tolosa E, Vilas D, Pont-Sunyer C, Orr-Urtreger A, Hausdorff JM, Giladi N.

Mov Disord. 2016 Oct;31(10):1527-1534. doi: 10.1002/mds.26720.

Supplemental Content

Support Center